Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray,

Acquisitions, Clinical Trial Results, Date Extensions and Financial Results -
       Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip

PR Newswire

NEW YORK, September 2, 2013

NEW YORK, September 2, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Endo
Health Solutions Inc. (NASDAQ: ENDP), Astex Pharmaceuticals, Inc. (NASDAQ:
ASTX), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), Accuray Incorporated
(NASDAQ: ARAY), and BioScrip Inc. (NASDAQ: BIOS). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Endo Health Solutions Inc. Research Report

On August 28, 2013, Endo Health Solutions Inc. (Endo) announced that its
subsidiary, Qualitest, has reached a definitive agreement to acquire Boca
Pharmacal, a privately held specialty generics company, for $225 million in
cash. According to Endo, the acquisition is expected to generate EBITDA of
approximately $50 million in full-year 2013 on a standalone basis. Rajiv de
Silva, President and CEO of Endo, said, "The acquisition is aligned with our
current generics footprint and will meaningfully accelerate the growth of
Qualitest in 2014. I believe that the revenue and earnings contribution of
this transaction, combined with the unique commercial portfolio and strong
pipeline of ANDAs, make this an ideal fit." Endo expects the deal to close
before the end of 2013, subject to standard regulatory requirements. The Full
Research Report on Endo Health Solutions Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-08-28/ENDP]

--

Astex Pharmaceuticals, Inc. Research Report

On August 28, 2013, Astex Pharmaceuticals, Inc. (Astex) reported topline
results from the ongoing Phase 2 trial of SGI-110 in patients with AML and
MDS. The Company stated that as of the end of the June 2013 data cutoff, 67
AML patients had a minimum follow up of 3 months (50 patients representing the
complete cohort of relapsed/refractory AML, and 17 patients in the
treatment-naïve elderly AML not suitable for induction chemotherapy cohort).
According to Astex, the primary endpoint was overall remission rate (Complete
Remission or CR Complete Remission with Incomplete hematologic recovery or
CRi/CRp), and there were 8 remissions in relapsed/refractory AML and 9
remissions in treatment-naïve elderly AML for an overall complete remission
rate of (CR, CRi/CRP0 of 17/67) or 25%. The Full Research Report on Astex
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-28/ASTX]

--

Auxilium Pharmaceuticals, Inc. Research Report

On August 28, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced that
the U.S. Food and Drug Administration (FDA) has notified the Company that it
is extending the Prescription Drug Fee User Act (PDUFA) goal date for the
Company's supplemental biologics license application (sBLA) for XIAFLEX
(collagenase clostridium histolyticum) for the treatment of Peyronie's disease
(PD) from September 6, 2013 to December 6, 2013. Commenting on the extension,
Adrian Adams, CEO and President of Auxilium Pharmaceuticals, said, "While we
are disappointed in any delay of approval, we remain confident in the XIAFLEX
Peyronie's program and are committed to working with theFDAwhile they
complete their review. We are continuing to prepare for commercialization in
Peyronie's disease, assuming FDA approval by the revised PDUFA date."
According to the Company, the FDA has not requested for additional clinical
studies to be performed prior to the revised PDUFA action date. The Full
Research Report on Auxilium Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-08-28/AUXL]

--

Accuray Incorporated Research Report

On August 27, 2013, Accuray Incorporated (Accuray) reported its financial
results for Q4 FY 2013 and full-year FY 2013 (period ended June 30, 2013). The
Company's net revenue declined 15.6% YoY to $84.9 million during the quarter
and dropped 22.8% YoY to $316 million for full-year FY 2013. Net loss
attributable to stockholders was $18.7 million, or $0.25 per diluted share, in
Q4 FY 2013, compared to net loss of $20.3 million, or $0.28 per diluted share,
in Q4 FY 2012. For full-year FY 2013, net loss attributable to stockholders
was $103.2 million, or $1.41 per diluted share, compared to net loss of $72.0
million, or $1.02 per diluted share, in full-year FY 2012. Commenting on the
results, Joshua H. Levine, President and Chief Executive Officer of Accuray,
said, "This was the second quarter in which we have shown growth and
improvement in new order volume, driven by the actions we have taken to
improve the commercial focus and execution of our business. I am encouraged
that while we have seen improved commercial momentum, at the same time we have
also reduced operating expenses, resulting in significantly lower operating
losses and cash usage." The Full Research Report on Accuray Incorporated -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-28/ARAY]

--

BioScrip Inc. Research Report

On August 26, 2013, BioScrip Inc. (BioScrip) announced that it has completed
the previously announced acquisition of the business of CarePoint Partners
Holdings LLC and its subsidiaries (collectively, CarePoint Partners).
According to the Company, the acquisition of CarePoint Partners will enable
BioScrip to provide home infusion services to over 100,000 patients annually.
Rick Smith, President and CEO of BioScrip said, "This transaction marks
another step in our strategy to build national scale in our core infusion
business. We continue to see significant acquisition opportunities for
additional growth, market expansion and consolidation in this
highly-fragmented industry." The Full Research Report on BioScrip Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-28/BIOS]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders, +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.